

# Burns - Pipeline Review, H1 2020

<https://marketpublishers.com/r/BFABF8FEA92EN.html>

Date: February 2020

Pages: 108

Price: US\$ 2,000.00 (Single User License)

ID: BFABF8FEA92EN

## Abstracts

Burns - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2020, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 1, 19, 4 and 1 respectively.

Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Burns - Overview
- Burns - Therapeutics Development
- Burns - Therapeutics Assessment
- Burns - Companies Involved in Therapeutics Development
- Burns - Drug Profiles
- Burns - Dormant Projects
- Burns - Discontinued Products
- Burns - Product Development Milestones
- Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Burns, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Burns - Pipeline by AlgiPharma AS, H1 2020  
Burns - Pipeline by Alliance Pharma Plc, H1 2020  
Burns - Pipeline by Anterogen Co Ltd, H1 2020  
Burns - Pipeline by Bioharmony Therapeutics Inc, H1 2020  
Burns - Pipeline by Biomendics LLC, H1 2020  
Burns - Pipeline by CFM Pharma Holding BV, H1 2020  
Burns - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020  
Burns - Pipeline by Combangio Inc, H1 2020  
Burns - Pipeline by Destiny Pharma Plc, H1 2020  
Burns - Pipeline by Energenesis Biomedical Co Ltd, H1 2020  
Burns - Pipeline by FirstString Research Inc, H1 2020  
Burns - Pipeline by FortuneRock (China) Ltd, H1 2020  
Burns - Pipeline by GNT Pharma Co Ltd, H1 2020  
Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020  
Burns - Pipeline by Hypo-Stream Ltd, H1 2020  
Burns - Pipeline by Madam Therapeutics BV, H1 2020  
Burns - Pipeline by Mallinckrodt Plc, H1 2020  
Burns - Pipeline by Marizyme Inc, H1 2020  
Burns - Pipeline by MediWound Ltd, H1 2020  
Burns - Pipeline by MicroCures Inc, H1 2020  
Burns - Pipeline by NeoMatrix Therapeutics Inc, H1 2020  
Burns - Pipeline by Novion Technologies Inc, H1 2020  
Burns - Pipeline by Phagelux Inc, H1 2020  
Burns - Pipeline by Riptide Bioscience Inc, H1 2020

Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2020  
Burns - Pipeline by Shulov Innovative Science Ltd, H1 2020  
Burns - Pipeline by Stemsynergy Therapeutics Inc, H1 2020  
Burns - Pipeline by TGV-Inhalonix Inc, H1 2020  
Burns - Pipeline by Theragnostic Technologies Inc, H1 2020  
Burns - Pipeline by TreeFrog Therapeutics SAS, H1 2020  
Burns - Pipeline by USV Pvt Ltd, H1 2020  
Burns - Pipeline by viDA Therapeutics Inc, H1 2020  
Burns - Pipeline by Washburn Therapeutics Inc, H1 2020  
Burns - Dormant Projects, H1 2020  
Burns - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Burns - Dormant Projects, H1 2020 (Contd..2), H1 2020  
Burns - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Burns, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AlgiPharma AS  
Alliance Pharma Plc  
Anterogen Co Ltd  
Bioharmony Therapeutics Inc  
Biomendics LLC  
CFM Pharma Holding BV  
Chrysalis BioTherapeutics Inc  
Combango Inc  
Destiny Pharma Plc  
Energenesis Biomedical Co Ltd  
FirstString Research Inc  
FortuneRock (China) Ltd  
GNT Pharma Co Ltd  
Hunan Sanqing Pharmaceutical Co Ltd  
Hypo-Stream Ltd  
Madam Therapeutics BV  
Mallinckrodt Plc  
Marizyme Inc  
MediWound Ltd  
MicroCures Inc  
NeoMatrix Therapeutics Inc  
Novion Technologies Inc

Phagelux Inc  
Riptide Bioscience Inc  
Se-cure Pharmaceuticals Ltd  
Shulov Innovative Science Ltd  
Stemsynergy Therapeutics Inc  
TGV-Inhalonix Inc  
Theragnostic Technologies Inc  
TreeFrog Therapeutics SAS  
USV Pvt Ltd  
viDA Therapeutics Inc  
Washburn Therapeutics Inc



## I would like to order

Product name: Burns - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/BFABF8FEA92EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BFABF8FEA92EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970